Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Neoadjuvant Cemiplimab in Stage II–IV (M0) Cutaneous Squamous Cell Carcinoma
2019-003007-35Phase 2Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Pathologic complete response rate. Started Oct 2019; status: active.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2019-003007-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003007-35.